Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data-Reference-Cited by-同舟云学术

Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data

Published:2019-12-16 Issue:6 Volume:34 Page:1008-1009
ISSN:0950-222X
Container-title:Eye
language:en
Short-container-title:Eye

Author:

Sharma Ashish,Hafeez Faridi M.,Kumar Nilesh^ORCID,Parachuri Nikulaa,Sharma Rohini,Kuppermann Baruch D.,Bandello Francesco,Loewenstein Anat,Regillo Carl D.

Publisher

Springer Science and Business Media LLC

Subject

Ophthalmology

Link

http://www.nature.com/articles/s41433-019-0745-z.pdf

Reference7 articles.

1. Sharma A, Reddy P, Kuppermann BD, Bandello F, Lowenstein A. Biosimilars in ophthalmology: “Is there a big change on the horizon?”. Clin Ophthalmol 2018;12:2137–43.

2. Milassin Á, Fábián A, Molnár T. Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective. Ther Adv Gastroenterol. 2019;12:1756284819842748.

3. Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389:2304–16.

4. Sharma S, Khan MA, Chaturvedi A, RE-ENACT Study Investigators Group. Real-Life Clinical Effectiveness of Razumab® (the World's First Biosimilar of Ranibizumab) in Retinal Vein Occlusion: A Subgroup Analysis of the Pooled Retrospective RE-ENACT Study. Ophthalmologica 2019;241:24–31.

5. Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspective. Br. J. Ophthalmol. (2019).

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ranibizumab Biosimilars in Treating Retinal Disorders: A Cost-Effective Revolution?;Drug Design, Development and Therapy;2024-02

2. Vascular endothelial growth factor (VEGF) antagonists for central retinal vein occlusion: an update on clinical progress;Expert Review of Ophthalmology;2023-11-17

4. Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER – survey);Expert Opinion on Biological Therapy;2023-02-19

5. Current and Novel Therapeutic Approaches for Treatment of Diabetic Macular Edema;Cells;2022-06-17